Analyzing serum bile acids to diagnose gastric cancer
Application of Serum Bile Acid Profile in the Diagnosis of Gastric Cancer
This study is testing if measuring bile acids in the blood can help doctors find gastric cancer earlier in people aged 18-70.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Xijing Hospital of Digestive Diseases Academic / other |
| Locations | 1 site (Xi'an, Shaanxi) |
| Trial ID | NCT06031779 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the composition and levels of serum bile acids in patients diagnosed with gastric cancer compared to those without gastric lesions. By detecting the serum bile acid profile, the study seeks to develop new serological diagnostic methods for the early diagnosis and treatment of gastric cancer. Participants will include both genders aged 18-70, with specific inclusion and exclusion criteria to ensure the integrity of the results.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-70 with either early or advanced gastric cancer, or those without gastric lesions.
Not a fit: Patients with conditions affecting bile acid metabolism or those on medications that influence bile acid levels may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a new diagnostic tool for early detection of gastric cancer, potentially improving patient outcomes.
How similar studies have performed: While the approach of using serum bile acids as a biomarker is promising, it is relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age between 18-70, both gender; 2. The gastric cancer group was early gastric cancer or advanced gastric cancer diagnosed by endoscopic examination and pathological biopsy. The non-gastric cancer group included patients without gastric lesions, superficial gastritis, chronic atrophic gastritis, intestinal metaplasia or dysplasia diagnosed by gastroscopy or pathological biopsy; 3. Informed consent was obtained. Exclusion Criteria: 1. The patients have diseases that affect bile acid metabolism, such as liver cirrhosis, gallstones or inflammatory bowel disease, Behcet's disease, etc; 2. Due to other diseases, the patient took drugs affecting bile acid metabolism, such as cholestyramine, anti-inflammatory Lidan tablets, Danshu capsules, ursodeoxycholic acid, obticholic acid, Schisandrin B, tanshinone ⅡA, Yinzhihuang, etc; 3. Pregnant women; 4. Primary tumors of other systems were diagnosed; 5. Those with poor physiopathological conditions, such as chronic kidney disease requiring long-term dialysis; 6. Patients with mental illness; 7. Patients who have received radiotherapy or surgery previously; 8. Those with poor adherence or difficult to follow up.
Where this trial is running
Xi'an, Shaanxi
- Xijing Hosipital of Digestive Disease — Xi'an, Shaanxi, China (Recruiting)
Study contacts
- Study coordinator: Nuo Yao
- Email: 785356949@qq.com
- Phone: +86 15319121701
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.